Stockscreener 앱 받기
2.81
2.18%
0.06
전일 마감가:
$2.75
열려 있는:
$2.75
하루 거래량:
602.20K
Relative Volume:
0.53
시가총액:
$186.95M
수익:
$488.00K
순이익/손실:
$-41.44M
주가수익비율:
-3.0215
EPS:
-0.93
순현금흐름:
$-31.47M
1주 성능:
+5.64%
1개월 성능:
+0.00%
6개월 성능:
+8.91%
1년 성능:
-24.87%
1일 변동 폭
$2.735
$2.83
1주일 범위
$2.595
$2.91
52주 변동 폭
$2.01
$5.6395
Cardiff Oncology Inc Stock (CRDF) Company Profile
명칭
Cardiff Oncology Inc
전화
858-952-7570
주소
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
CRDF을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRDF
Cardiff Oncology Inc
|
2.81 | 176.96M | 488.00K | -41.44M | -31.47M | -0.93 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-06 | 개시 | Craig Hallum | Buy |
| 2022-01-05 | 개시 | William Blair | Outperform |
| 2021-12-08 | 개시 | Robert W. Baird | Outperform |
| 2021-08-09 | 재개 | Maxim Group | Buy |
| 2020-10-22 | 개시 | H.C. Wainwright | Buy |
| 2020-10-08 | 개시 | Piper Sandler | Overweight |
모두보기
Cardiff Oncology Inc 주식(CRDF)의 최신 뉴스
13,124 Shares in Cardiff Oncology, Inc. (NASDAQ:CRDF) Bought by Voya Investment Management LLC - Defense World
Cardiff Oncology Reports Increased Losses Amid Rising R&D Costs - TipRanks
Raymond James Financial Inc. Purchases New Shares in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Cardiff Oncology (CRDF) Upgraded to Buy: Here's What You Should Know - Nasdaq
Cardiff Oncology: Buying The First-Line Onvansertib Strategy (NASDAQ:CRDF) - Seeking Alpha
Barclays PLC Purchases 9,507 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Wells Fargo & Company MN Purchases 8,851 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Cardiff Oncology First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo
Mariner LLC Makes New $61,000 Investment in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Cardiff Oncology stock target raised to $18 by H.C. Wainwright - Investing.com Canada
Cardiff Oncology (CRDF) Gains Analyst Confidence with Price Target Increase | CRDF Stock News - GuruFocus
Cardiff Oncology (CRDF) Price Target Increased by Analyst | CRDF Stock News - GuruFocus
Cardiff Oncology: Q1 Earnings Snapshot - New Haven Register
Cardiff Oncology earnings missed by $0.01, revenue topped estimates - Investing.com Canada
Promising Clinical Trial Developments Drive Buy Rating for Cardiff Oncology - TipRanks
Cardiff Oncology (CRDF) Reports Strong Q1 Revenue and Advances Cancer Therapy | CRDF Stock News - GuruFocus
Cardiff Oncology (CRDF) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Cardiff Oncology Q1 2025 Earnings: EPS Misses at -$0.20, Revenue Slightly Beats at $0.11 Million - GuruFocus
Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update - GlobeNewswire
Financial Comparison: 4D Molecular Therapeutics (NASDAQ:FDMT) and Cardiff Oncology (NASDAQ:CRDF) - Defense World
Cardiff Oncology: Expecting Massive Updates In Colon Cancer Soon - Seeking Alpha
Investing in Cardiff Oncology Inc (CRDF) might be an excellent idea, but the stock is currently overvalued/undervalued - uspostnews.com
Analysts review Cardiff Oncology Inc’s rating - knoxdaily.com
Cardiff Oncology Inc Inc. (CRDF) Price Performance: The Role of Supply and Demand - investchronicle.com
Market Highlights: Cardiff Oncology Inc (CRDF) Ends on a High Note at 2.95 - DWinneX
Cardiff Oncology Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView
Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares Purchased by Geode Capital Management LLC - Defense World
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge - ADVFN
Cardiff Oncology Inc [CRDF] Records 50-Day SMA of $3.62 - knoxdaily.com
Market Insights: Cardiff Oncology Inc (CRDF)’s Notable Drop of -3.61, Closing at 2.94 - DWinneX
Cardiff Oncology (CRDF) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
A Tale of Resilience: Cardiff Oncology Inc Amid Stock Market Turbulence - investchronicle.com
Cardiff Oncology (CRDF) Secures New U.S. Patent for Cancer Treat - GuruFocus
Cardiff Oncology (CRDF) Secures New U.S. Patent for Cancer Treatment Method | CRDF Stock News - GuruFocus
Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients - GlobeNewswire
A look into Cardiff Oncology Inc (CRDF)’s deeper side - Sete News
Cardiff Oncology Wins Crucial Patent: Breakthrough Cancer Drug Now Covers All Bevacizumab-Naïve Patients - Stock Titan
A closer look at Cardiff Oncology Inc (CRDF) is warranted - uspostnews.com
Cardiff Oncology, Inc.'s (NASDAQ:CRDF) market cap touched US$186m last week, benefiting both individual investors who own 56% as well as institutions - simplywall.st
Cardiff Oncology (CRDF) Completes Enrollment for Phase 2 Trial i - GuruFocus
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing R - GuruFocus
Cardiff Wraps Up Enrollment in Phase 2 Trial of Prospective Colorectal Cancer Treatment - MarketScreener
Cardiff Oncology Announces Completion of Enrollment in Phase 2 C - GuruFocus
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | CRDF Stock News - GuruFocus
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Cardiff Oncology (CRDF) Completes Enrollment for Phase 2 Trial in Colorectal Cancer | CRDF Stock News - GuruFocus
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Cardiff Oncology Completes Patient Enrollment in Phase 2 CRDF-004 Trial for RAS-Mutated Metastatic Colorectal Cancer, Additional Data Expected in 1H 2025 - Nasdaq
Cardiff Oncology Awards Strategic Compensation Package: Inside the Latest Employee Stock Options Grant - Stock Titan
Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer - GlobeNewswire
Major Progress: First-line Colorectal Cancer Treatment Trial Hits Key Milestone - Stock Titan
Cardiff Oncology Inc (CRDF) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Cardiff Oncology Inc 주식 (CRDF) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Levine James E. | Chief Financial Officer |
Dec 18 '24 |
Buy |
5.00 |
2,400 |
12,000 |
67,716 |
| Levine James E. | Chief Financial Officer |
Dec 16 '24 |
Buy |
3.83 |
2,564 |
9,820 |
62,564 |
| TANNENBAUM RENEE P | Director |
Dec 12 '24 |
Buy |
3.42 |
10,000 |
34,224 |
20,000 |
| PACE GARY W | Director |
Dec 11 '24 |
Buy |
2.60 |
350,115 |
910,299 |
1,047,876 |
| PACE GARY W | Director |
Dec 11 '24 |
Buy |
2.60 |
11,500 |
29,900 |
1,059,376 |
1.54%
7.58%
자본화:
|
볼륨(24시간):